The role of CD4+ T cell responses in antitumor immunity.
While most of the focus in cancer immunology is on CD8+ cytotoxic T lymphocyte responses, recent evidence indicates that CD4+ T cells are an equally critical component of the antitumor immune response. Successful immunity to cancer will therefore require activation of tumor-specific CD4+ T cells. Tumor antigens recognized by CD4+ T cells that are restricted by MHC class II are beginning to be defined in both murine and human tumors. These will provide the basis for new generations of antigen-specific tumor vaccines.
Pardoll
D M
DM
Department of Oncology, Johns Hopkins University School of Medicine, 720 Rutland Avenue/Ross 364, Baltimore, MD 21205, USA.
Topalian
S L
SL
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000502:physiology; D006801:Humans; D007108:Immune Tolerance; D009369:Neoplasms / Q000276:immunology*
D000951:Antigens, Neoplasm; D000949:Histocompatibility Antigens Class II